MedTrace Logo

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

NCT04048564 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-09-28

No results posted yet for this study

Summary

This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib. This study aims at better qualifying the ponatinib benefit-risk balance in real life and in relation with CML patients' therapeutic history.

Conditions

  • Chronic Myeloid Leukemia

Sponsors & Collaborators

  • Incyte BioSciences France

    lead INDUSTRY

Principal Investigators

  • Ali G. Turnan, MD, PhD · Paris Sud University Hospitals-Bicetre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2022-12-31
Completion
2023-07-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04048564 on ClinicalTrials.gov